NCT05644483View on ClinicalTrials.gov

Effect of Remimazolam and Propofol on Hemodynamic Stability in Prone Position

PHASE4CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

January 25, 2023

Study Completion Date

January 25, 2023

Conditions
Hemodynamic Instability
Interventions
DRUG

Remimazolam

Remimazolam: loading (6mg/kg/hr) + continuous infusion (1-2mg/kg/hr)

DRUG

Propofol

Propofol: target controlled infusion: 2-3mcg/mL

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER